CUPERTINO, Calif., Sept. 4, 2024 /PRNewswire/ -- DURECT Company (Nasdaq: DRRX), a late-stage biopharmaceutical firm pioneering the event of epigenetic…
Our selection of the week's biggest research news and features sent directly to your inbox. Enter your email address, confirm you're happy to receive our emails.